With the new Labour government pledging to 'build an NHS fit for the future', an injection of money, whilst welcome, will not be enough - it must be rolled out in a measured and integrated way that works more closely with the private sector in order to make a real difference, says RSM UK.
News
Presentation in Boston at 9th Microbiome Movement Drug Development Summit, 10-12 July 2024
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth.
The NHS’ Health Research Authority (HRA) recently published its draft template Investigator Initiated Study Agreement (IIS Agreement)1 and called for comments on the draft.
According to the HRA, and in a similar way to the other model agreements used for other types of clinical trials conducted in the UK, the IIS Agreement is intended to act as a “standard contract agreement template” for use between non-commercial sponsors and commercial organisations providing support for investigator-initiated studies.
Key appointment to support continued UK and US team expansion
AMSBIO has launched a Glucagon-Like Peptide 1 Receptor (GLP-1R) reporter cell line.
The June edition of our People Pathways newsletter is now available to read here. You will find:
- One Nucleus upcoming courses
- Our new BLSA SIG on Neurodiversity
- A Blog by Tony Jones, CEO of One Nucleus
- Guest article by Aon
You can also read last month's newlsetter here.